|
1
|
Xie RF, Li ZC, Gao B, Shi ZN and Zhou X:
Bufothionine, a possible effective component in cinobufocini
injection for hepatocellular carcinoma. J Ethnopharmacol.
141:692–700. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Qi F, Li A, Inagaki Y, Kokudo N, Tamura S,
Nakata M and Tang W: Antitumor activity of extracts and compounds
from the skin of the toad Bufo bufo gargarizans Cantor. Int
Immunopharmacol. 11:342–349. 2011. View Article : Google Scholar
|
|
3
|
Gong ZP and Chen T: Studies on analgesic
mechanism based on opioid receptor for cinobufagin injection. Chin
J Exp Tradit Med. 16:1202010.In Chinese.
|
|
4
|
Liu HM, Zheng YL and Liu XL: A Clinical
study of efficacy of cinobufagin injection combined with ND formula
in medium and advanced esophageal patients. Chin J Exp Tradit Med.
17:2352011.In Chinese.
|
|
5
|
Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo
N, Li XK and Tang W: Chinese herbal medicines as adjuvant treatment
during chemo- or radio-therapy for cancer. Biosci Trends.
4:297–307. 2010.
|
|
6
|
Su YH, Yin XC, Xie JM, et al: Inhibition
effects of three kinds of bufotoxins on human SMMC-7721 and
BEL-7402 hepatoma cells lines. Acad J Second Mil Med Univ.
24:3932004.
|
|
7
|
Yang LH, Jing XQ and Zhang W: Studies on
the chemical constituents from the skin of Bufo bufo gargarizans
cantor. J Shenyang Pharm Univ. 17:292–295. 2000.
|
|
8
|
Sun Y and Shi KY: Primary carcinoma of the
liver. Manual of Medical Oncology. Fifth Edition. Sun Y: People’s
medical publishing house; Bei Jing: pp. 5392007
|
|
9
|
Zhou LX and Guo JM: Research progress in
targeted therapy for hepatocellular carcinoma. J Oncol.
15:1562009.
|
|
10
|
Cheng AL, Kang YK, Chen Z, et al: Efficacy
and safety of sorafenib in patients in the Asia-Pacific region with
advanced hepatocellular carcinoma: a phase III randomised,
double-blind placebo controlled tril. Lancet Oncol. 10:25–34. 2009.
View Article : Google Scholar
|
|
11
|
Cui X, et al: New reseach approaches in
DNA topoisomerase II targets and antitumor drug. Qingdao Med J.
36:434–437. 2004.In Chinese.
|
|
12
|
Sun Y, Shan LJ, Liu YJ and Cui XN: The
effect of cinobufacini injection on DNA topoisomerase I of human
hepatocellular carcinoma HepG-2 cells. Chin J Oncol. 19:410–413.
2010.In Chinese.
|
|
13
|
Belluti S, Basile V, Benatti P, Ferrari E,
Marverti G and Imbriano C: Concurrent inhibition of enzymatic
activity and NF-Y-mediated transcription of Topoisomerase-IIα by
bis-DemethoxyCurcumin in cancer cells. Cell Death Dis. 4:e7562013.
View Article : Google Scholar
|
|
14
|
Bradford MM: A rapid and sensitive for the
quantitation of microgram quantitites of protein utilizing the
principle of protein-dye binding. Anal Biochem. 72:248–254. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stoscheck CM: Quantitation of protein.
Methods Enzymol. 182:50–68. 1990.PubMed/NCBI
|
|
16
|
Zhong JS, Chen GP and Guo JW: Clinical
observation on HuaChanSu in treating hepatocellular carcinoma after
trans-arterial chemoembolization (TACE). Cancer Prev Treat.
29:67–69. 2002.
|
|
17
|
Meng ZQ, Yang PY, Shen YH, et al: Pilot
study of huachansu in patients with hepatocellular carcinoma,
nonsmall-cell lung cancer, or pancreatic cancer. Cancer.
115:5309–5318. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP
and Pan BR: Efficacy and safety of gemcitabine-oxaliplatin combined
with huachansu in patients with advanced gallbladder carcinoma.
World J Gastroenterol. 14:5210–5216. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yeh JY and Huang WJ: Effects of bufalin
and cinobufagin on the proliferation of androgen dependent and
independent prostate cancer cells. Prostate. 54:112–124. 2003.
View Article : Google Scholar
|
|
20
|
Yu CH, Kan SF, Pu HF, Jea Chien E and Wang
PS: Apoptotic signaling in bufalin- and cinobufagin-treated
androgen-dependent and -independent human prostate cancer cells.
Cancer Sci. 99:2467–2476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qi F, Inagaki Y, Gao B, et al: Bufalin and
cinobufagin induce apoptosis of human hepatocellular carcinoma
cells via Fas- and mitochondria-mediated pathways. Cancer Sci.
102:951–958. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qi F, Li A, Inagaki Y, et al: Antitumor
activity of extracts and compounds from the skin of the toad Bufo
bufo gargarizans Cantor. Int Immunopharmacol. 11:342–349. 2011.
View Article : Google Scholar
|
|
23
|
Denny WA and Baguley BC: Dual
topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem.
3:339–353. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fayad W, Fryknäs M, Brnjic S, Olofsson MH,
Larsson R and Linder S: Identification of a novel topoisomerase
inhibitor effective in cells overexpressing drug efflux
transporters. PLoS One. 4:e72382009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Giovanella BC, Stehlin JS, Wall ME, et al:
DNA topoisomerase I-targeted chemotherapy of human colon cancer
inxenografts. Science. 246:1046–1048. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Potmesil M, Hsiang YH, Liu LF, et al:
Resistance of humanleukemic and normal lymphocytes to drug-induced
DNAcleavage and low levels of DNA topoisomerase II. Cancer Res.
48:3537–3543. 1988.PubMed/NCBI
|
|
27
|
Rho YH, Lee BW, Park KH, et al:
Cudraflavanone A purified from Cudrania tricuspidata induces
apoptotic cell death of human leukemia U937 cells, at least in
part, through the inhibition of DNA topoisomerase I and protein
kinase C activity. Anti-cancer Drugs. 18:1023–1028. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan YQ, Yuan G and Yang YW: DNA
topoisomerase IIα and tumor. Med Imformation. 2:4152011.
|
|
29
|
Squires S, Ryan AJ, Strutt HL, Smith PJ
and Johnson RT: Deoxyguanosine enhances the cytotoxicity of the
topoisomerase I inhibitor camptothecin by reducing the repair of
double-strand breaks induced in replicating DNA. J Cell Sci.
100:883–893. 1991.PubMed/NCBI
|
|
30
|
Huang X, Halicka HD, Traganos F, et al:
Cytometric assessment of DNA damage in relation to cell cycle phase
and apoptosis. Cell Prolif. 38:223–243. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu YP, Chen HL, Tzeng CC, et al: TCH-1030
targeting on topoisomerase I induces S-phase arrest, DNA
fragmentation, and cell death of breast cancer cells. Breast Cancer
Res Treat. 138:383–393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hofland K, Petersen BO, Falck J, Helin K,
Jensen PB and Sehested M: Differential cytotoxic pathways of
topoisomerase I and II anticancer agents after overexpression of
the E2F-1/DP-1 transcription factor complex. Clin Cancer Res.
6:1488–1497. 2000.PubMed/NCBI
|
|
33
|
Nitiss John L and Wang James C: Mechanisms
of cell killing by drugs that trap covalent complexes between DNA
topoisomerases and DNA. Mol Harmacology. 50:1095–1102. 1996.
|
